Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

Phase 2positiveOpamtistomigbevacizumabPositive

AI Analysis

Summary

Nanjing Leads Biolabs announced that its Phase 2 study of Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody combined with bevacizumab, successfully completed the safety run-in phase in first-line hepatocellular carcinoma and has advanced to the expansion phase following positive efficacy signals.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Successfully completed safety run-in phase and advanced to expansion phase following positive efficacy signals

Importance:6/10

Sentiment:

0.75

oncologyhepatocellular carcinomabispecific antibodyimmunotherapyPhase 2combination therapy

Related Companies

$CHHE $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on August 6, 2026 12:53 AM

Read Original